AN2 rises after early-stage trial data for Chagas disease therapy

AN2 Therapeutics (ANTX) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic infection known as ...
Fintel on MSN

Leerink Partners upgrades AN2 Therapeutics (ANTX)

Fintel reports that on May 14, 2026, Leerink Partners upgraded their outlook for AN2 Therapeutics (NasdaqGS:ANTX) from Market Perform to Outperform. Analyst Price Forecast Suggests 78.06% Downside As ...